AI Medical Service
AM
About
AI Medical Service Inc. (AIM) is a Japanese med-tech company focused on developing AI-powered software for the early detection of gastrointestinal cancers. Their technology analyzes endoscopic images to assist physicians in identifying cancerous lesions, aiming to reduce missed diagnoses and improve patient outcomes globally.
Key facts
- Website
- aims.inc
- Headquarters
- Tokyo, Japan
- Founded
- 2017
- Total funding
- $122M (Series C)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 26 Apr 2022 | Series C | $70M | SoftBank Vision Fund 2 |
| 4 Oct 2019 | Series B | $43M | Globis Capital |
| 1 Aug 2018 | Series A | $9M |
AI Medical Service scores 22. Does yours?
That is its Agent Readiness: how well ChatGPT, Claude and the other agents can read and use a site. Paste your website and you get yours in about a minute.
Add first review
Frequently asked
How much funding has AI Medical Service raised?
AI Medical Service has raised a total of $122M in funding. The most recent round on record is Series C.
What is AI Medical Service's current status?
AI Medical Service's current operating status is: Inactive.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for AI Medical Service
